Table 1.
Demographic baseline characteristics of study participants.
| NMOSD | MOGAD | MS | |
|---|---|---|---|
| Number of patients | 40 | 40 | 54 |
| F:M, n (%) | 32 (80.0): 8 (20.0) | 22 (55.0): 18 (45.0) | 35 (64.8): 19 (35.2) |
| Median age (min-max), y | 51.8 (3.5-86.2) | 23.7 (3.3-72.0) | 31.2 (19.5-58.3) |
| Participants <18 y | 5 (12.5) | 17 (42.5) | 0 (0.0) |
| Median disease duration (min-max), mo | 59.0 (0.0-373.0) | 12.0 (0.0-202.0) | 0.0 (0.0-173.0) |
| Monophasic disease course, n (%) | 4/23 (17.4) | 16/32 (50.0) | n.a. |
| Sample taking during relapse, n (%) | 7/23 (30.4) | 12/32 (37.5) | n.a. |
| Sample taking during remission, n (%) | 16/23 (69.6) | 20/32 (62.5) | n.a. |
| Immunosuppressive treatment in the last 30d, n (%) | 7/23 (30.4) (2 PRED, 2 AZA, 1 MMF, 1 TOC, 1 RTX) |
10/19 (52.6) (8 IVIG, 2 RTX) |
0/54 |
| Long-term treatment since disease onset, n (%) | 20/23 (87.0) (*: 16 RTX, 7 AZA, 7 PRED, 3 TOC, 2 CYC, 2 MMF, 2 PLEX, 1 MTX, 1 IVIG, 1 Tx not further described) |
9/18 (50.0) (6 IVIG, 3 RTX) |
5/54 (9.3) (2 S1P receptor modulator, 3 DMF) |
| Median antibody titer at baseline (min-max) [available from n (%) patients] | 640 (20-20,480) [25 (62.5)] | 2050 (320-20,480) [40 (100%)] | |
| Number of patients with follow-up samples available | 25 | 40 | n.a. |
| Median time until follow-up sample (min-max), mo | 6.0 (4.0-24.0) | 12.0 (6.0-38.0) | |
| EDSS at sample collection, median (min-max) | 1.0 (0.0-6.0) | ||
| MS subtype at sample collection | CIS:3 RRMS: 46 SPMS: 1 PPMS: 4 |
AZA, azathioprine; CIS, clinically isolated syndrome; CYC, cyclophosphamide; d,days; DMF, dimethyl fumarat; EDSS, expanded disability status scale; F, female; IVIG, intravenous immunoglobulin; M, male; mo, months; MMF, mycophenolate mofetil; MOGAD, myelin oligodendrocyte glycoprotein associated disease; MS, multiple sclerosis; MTX, methotrexate; n.a., not analyzed/data not available; NMOSD, neuromyelitis optica spectrum disorder; PLEX, plasma exchange; PRED, prednisone; PPMS, primary progressive multiple sclerosis; RRMS, relapsing remitting multiple sclerosis; RTX, rituximab; S1P, sphingosine-1-phosphate; SD, standard deviation; SPMS, secondary progressive multiple sclerosis; TOC, tocilizumab; Tx, treatment; y, years;*some patients received multiple different treatments over time.